Nothing Special   »   [go: up one dir, main page]

DE69832984D1 - DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN - Google Patents

DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN

Info

Publication number
DE69832984D1
DE69832984D1 DE69832984T DE69832984T DE69832984D1 DE 69832984 D1 DE69832984 D1 DE 69832984D1 DE 69832984 T DE69832984 T DE 69832984T DE 69832984 T DE69832984 T DE 69832984T DE 69832984 D1 DE69832984 D1 DE 69832984D1
Authority
DE
Germany
Prior art keywords
cyclosporine
substitution
disclosed
derivatives
uninterrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69832984T
Other languages
English (en)
Other versions
DE69832984T2 (de
Inventor
Selvaraj Naicker
W Yatscoff
T Foster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISOTECHNIKA,INC., EDMONTON, ALBERTA, CA
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Publication of DE69832984D1 publication Critical patent/DE69832984D1/de
Application granted granted Critical
Publication of DE69832984T2 publication Critical patent/DE69832984T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69832984T 1997-10-08 1998-10-08 DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN Expired - Lifetime DE69832984T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6136097P 1997-10-08 1997-10-08
US61360P 1997-10-08
PCT/IB1998/001693 WO1999018120A1 (en) 1997-10-08 1998-10-08 Deuterated cyclosporine analogs and their use as immunomodulating agents

Publications (2)

Publication Number Publication Date
DE69832984D1 true DE69832984D1 (de) 2006-02-02
DE69832984T2 DE69832984T2 (de) 2006-09-21

Family

ID=22035297

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69840586T Expired - Fee Related DE69840586D1 (de) 1997-10-08 1998-10-08 Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
DE69832984T Expired - Lifetime DE69832984T2 (de) 1997-10-08 1998-10-08 DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69840586T Expired - Fee Related DE69840586D1 (de) 1997-10-08 1998-10-08 Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien

Country Status (15)

Country Link
US (3) US6613739B1 (de)
EP (1) EP0991660B8 (de)
JP (6) JP4261049B2 (de)
KR (1) KR100585348B1 (de)
AT (2) ATE423130T1 (de)
AU (1) AU750245B2 (de)
BR (1) BR9811716A (de)
CA (1) CA2298572C (de)
DE (2) DE69840586D1 (de)
DK (1) DK0991660T3 (de)
ES (1) ES2256959T3 (de)
HK (1) HK1026432A1 (de)
NO (1) NO324042B1 (de)
NZ (1) NZ502362A (de)
WO (1) WO1999018120A1 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066106A2 (en) * 1999-04-30 2000-11-09 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US6784156B2 (en) * 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
US20030087813A1 (en) 2001-10-12 2003-05-08 Or Yat Sun Cyclosporin analogs for the treatment of lung diseases
CA2727642C (en) * 2001-10-19 2014-02-04 Isotechnika Inc. Synthesis of cyclosporin analogs
IL160763A0 (en) * 2001-10-19 2004-08-31 Isotechnika Inc Synthesis of cyclosporin analog
US20040110666A1 (en) * 2002-12-04 2004-06-10 Or Yat Sun Cyclosporins for the treatment of immune disorders
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
WO2004082629A2 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
US20040266669A1 (en) * 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1729814A2 (de) * 2004-04-01 2006-12-13 Cardiome Pharma Corp. Pegylierte ionenkanalmodulatoren
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
AU2005326322B2 (en) * 2004-07-01 2009-02-05 Yale University Targeted and high density drug loaded polymeric materials
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
WO2006014872A2 (en) * 2004-07-29 2006-02-09 Amr Technology, Inc. Novel processes for stereoselective synthesis of trans isatx 247
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006039164A2 (en) * 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7361636B2 (en) * 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US8692002B2 (en) * 2004-11-18 2014-04-08 Cardiome Pharma Corp. Synthetic process for aminocyclohexyl ether compounds
CA2592343A1 (en) * 2004-12-17 2006-06-22 Isotechnika Inc. Metabolites of cyclosporin analogs
AU2006203946B2 (en) * 2005-01-03 2009-07-23 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP1875250B1 (de) * 2005-04-06 2010-01-27 Abbott Laboratories Verfahren zur messung immunsuppressiver tacrolimus-, sirolimus- und cyclosporin-a-komplexe in einer blutprobe
EP1893218A4 (de) 2005-06-01 2011-01-12 Univ Michigan Ungelöste benzodiazepin-zusammensetzungen und verfahren
MX346530B (es) 2005-06-15 2017-03-22 Cardiome Pharma Corp Procedimiento sintético para la preparación de compuestos de éter aminociclohexílico.
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
NZ568254A (en) 2005-11-01 2011-06-30 Univ Michigan 1,4-Benzodiazepine-2,5-diones for regulating cell death and treating autoimmune diseases
CA2628570A1 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
WO2007064697A1 (en) 2005-12-01 2007-06-07 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US8155649B2 (en) * 2006-05-12 2012-04-10 Shared Spectrum Company Method and system for classifying communication signals in a dynamic spectrum access system
NZ573452A (en) 2006-06-09 2011-09-30 Univ Michigan Compositions and methods relating to novel compounds and targets thereof
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
US20100151436A1 (en) * 2007-03-02 2010-06-17 Fong Peter M Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
CN101662940A (zh) * 2007-03-09 2010-03-03 密执安州立大学董事会 与新化合物及其靶标有关的组合物和方法
EP2514740B1 (de) 2007-03-15 2018-12-19 Auspex Pharmaceuticals, Inc. Deuterierte o-desmethylvenlafaxine mit serotoninergischer und/oder norepinephrinergischer aktivität
WO2009018424A2 (en) * 2007-08-01 2009-02-05 Emory University Methods for determination of protein phosphatase activity, and uses in predicting therapeutic outcomes
AU2008298870C1 (en) 2007-09-14 2014-10-09 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
CN101918375A (zh) 2007-11-06 2010-12-15 密歇根大学董事会 在皮肤病症的治疗中有用的苯并二氮杂*酮化合物
EP2268604B1 (de) 2008-03-14 2017-02-15 Retrotope, Inc. Krebstherapien unter verwendung von isotopsubstituiertem lysin
AR072511A1 (es) * 2008-07-15 2010-09-01 Theracos Inc Derivados deuterados de bencilbenceno y metodos de uso. composicion farmaceutica.
CA2732146A1 (en) 2008-07-30 2010-02-04 Isotechnika Pharma Inc. Nonimmunosuppressive cyclosporine analogue molecules
CA2735722A1 (en) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
KR20160079147A (ko) * 2008-09-03 2016-07-05 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
AU2009291632B2 (en) 2008-09-11 2013-04-04 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
JP5773877B2 (ja) * 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
NZ594755A (en) 2009-01-30 2013-12-20 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
EP2470020A4 (de) 2009-09-18 2013-03-13 Univ Michigan Benzodiazepinonverbindungen und behandlungsverfahren damit
JP5934102B2 (ja) 2009-10-30 2016-06-15 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ誘導体による酸化ストレス障害の緩和
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
ES2703752T3 (es) 2009-11-17 2019-03-12 Univ Michigan Regents 1,4-Benzodiazepina-2,5-dionas y compuestos relacionados que presentan propiedades terapéuticas
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
KR102011339B1 (ko) 2010-12-15 2019-08-16 콘트라빌 파마슈티컬스, 인코퍼레이티드 아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자
WO2012145426A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
EP2701698B1 (de) 2011-04-26 2020-12-23 Retrotope, Inc. Erkrankungen mit pufa-oxidierung
CA2834342C (en) 2011-04-26 2021-08-31 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
DK2701695T3 (da) 2011-04-26 2019-06-17 Retrotope Inc Neurodegenerative lidelser og muskelsygdomme, der involverer polyumættede fedtsyrer
EP2701697B1 (de) 2011-04-26 2020-03-25 Retrotope, Inc. Oxidative netzhauterkrankungen
DE102011111991A1 (de) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
SG11201402401TA (en) 2011-11-18 2014-06-27 Codexis Inc Biocatalysts for the preparation of hydroxy substituted carbamates
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2014165679A1 (en) 2013-04-03 2014-10-09 Allertein Therapeutics, Llc Novel nanoparticle compositions
MX2016002458A (es) 2013-08-26 2016-08-08 Enanta Pharm Inc Análogos novedosos de ciclosporina para prevenir o tratar la infección por hepatitis c.
US10428331B2 (en) 2014-01-16 2019-10-01 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US10730821B2 (en) 2015-11-23 2020-08-04 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
CA3087009A1 (en) 2018-01-12 2019-07-18 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation
US11584779B2 (en) 2018-10-19 2023-02-21 Teva Pharmaceuticals International Gmbh Solid state forms of voclosporin
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
CA3172535A1 (en) * 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
EP4201952A1 (de) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Verfahren zur kontrollierten synthese von voclosporin
WO2024157132A1 (en) * 2023-01-25 2024-08-02 Indena S.P.A. Process for the preparation of an intermediate useful for the synthesis of voclosporin

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210581A (en) 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (de) 1975-11-04 1979-12-28 Sandoz Ag
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DE2819094A1 (de) 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en) 1979-03-12 1980-05-06 Merck & Co., Inc. Antibiotic A43F
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
ATE43335T1 (de) 1980-02-14 1989-06-15 Sandoz Ag Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung.
FR2487198A1 (fr) 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
US4384996A (en) 1981-01-09 1983-05-24 Sandoz Ltd. Novel cyclosporins
CH667274A5 (de) 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NZ212051A (en) 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8422253D0 (en) 1984-09-04 1984-10-10 Sandoz Ltd Organic compounds
EP0194972B1 (de) 1985-03-11 1992-07-29 Sandoz Ag Cyclosporine
US4765980A (en) 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4764503A (en) 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
HU205861B (en) 1986-12-19 1992-07-28 Sandoz Ag Process for producing hydrosole of pharmaceutically effective material
US5427960A (en) 1987-03-27 1995-06-27 Abbott Laboratories Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
US5239057A (en) 1987-03-27 1993-08-24 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
EP0283801A3 (de) * 1987-03-27 1990-05-30 Abbott Laboratories Fluoreszenz-Polarisations-Test für Cyclosporin A und Metaboliten und verwandte Immunogene und Antikörper
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ATE95193T1 (de) * 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
ATE110784T1 (de) 1987-06-19 1994-09-15 Sandoz Ag Zyklische peptolide.
EP0373260B1 (de) * 1987-06-22 1994-03-09 Merck & Co. Inc. Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen
GB8717300D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
GB8717299D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Peptides
US5227467A (en) 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
EP0391909B1 (de) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Cyclosporin-augenmittel
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5089390A (en) 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US5236899A (en) 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4914188A (en) 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5013719A (en) 1988-05-13 1991-05-07 Merrell Dow Pharmaceuticals Inc. Method of effecting immunosuppression
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
WO1990006763A1 (en) 1988-12-05 1990-06-28 The Trustees Of Columbia University In The City Of New York Novel derivatives of cyclosporine a, antibodies directed thereto and uses thereof
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5214130A (en) 1990-02-27 1993-05-25 Merck & Co., Inc. Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
EP0473961B1 (de) 1990-08-15 1996-01-03 Abbott Laboratories Immunotestreagenzien und Verfahren zur Bestimmung von Cyclosporin
DK0484281T4 (da) 1990-11-02 2001-02-05 Novartis Ag Cyclosporiner
US5115859A (en) 1990-12-21 1992-05-26 United Technologies Corporation Regenerable non-venting cooler for protective suit
DE59106428D1 (de) 1991-04-06 1995-10-12 Dresden Arzneimittel Verfahren zur fermentativen Herstellung und Isolierung von Cyclosporin A sowie neue Cyclosporin- bildende Stämme.
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
HU213553B (en) 1992-05-25 1997-07-28 Biogal Gyogyszergyar Process for isolating of cyclosporin-a
FI92334C (fi) 1992-12-30 1994-10-25 Leiras Oy Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
AU674233B2 (en) 1993-05-04 1996-12-12 Merck & Co., Inc. Cyclohexapeptidyl aminoalkyl ethers
EP0751926B1 (de) * 1994-03-25 2007-09-12 Isotechnika,Inc. Verbesserung der effektivität von arzneimitteln duren deuterierung
US5639852A (en) 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US5747330A (en) 1996-06-05 1998-05-05 Poli Industria Chimica Antibiotic producing microbe
US5709797A (en) 1996-06-05 1998-01-20 Poli Industria Chimica S.P.A. Method of isolating cyclosporins

Also Published As

Publication number Publication date
DK0991660T3 (da) 2006-02-13
JP2004143168A (ja) 2004-05-20
JP2007119489A (ja) 2007-05-17
CA2298572A1 (en) 1999-04-15
NO20001020L (no) 2000-02-29
BR9811716A (pt) 2000-07-18
ATE314388T1 (de) 2006-01-15
KR100585348B1 (ko) 2006-06-01
US20020132763A1 (en) 2002-09-19
NO324042B1 (no) 2007-07-30
KR20010030978A (ko) 2001-04-16
DE69840586D1 (de) 2009-04-02
AU9454298A (en) 1999-04-27
US6613739B1 (en) 2003-09-02
JP4261049B2 (ja) 2009-04-30
NO20001020D0 (no) 2000-02-29
US6605593B1 (en) 2003-08-12
HK1026432A1 (en) 2000-12-15
ATE423130T1 (de) 2009-03-15
EP0991660A1 (de) 2000-04-12
NZ502362A (en) 2001-05-25
DE69832984T2 (de) 2006-09-21
ES2256959T3 (es) 2006-07-16
JP2008222725A (ja) 2008-09-25
JP2008222724A (ja) 2008-09-25
EP0991660B1 (de) 2005-12-28
EP0991660B8 (de) 2006-04-05
JP2005343904A (ja) 2005-12-15
AU750245B2 (en) 2002-07-11
CA2298572C (en) 2002-04-09
JP2001519355A (ja) 2001-10-23
WO1999018120A1 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
DE69832984D1 (de) DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
Kruger et al. Electron capture dissociation of multiply charged peptide cations
Tomer et al. Fast-atom bombardment combined with tandem mass spectrometry for the determination of cyclic peptides
Kenny et al. Fragmentation studies of peptides: the formation of y ions
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
CA2235138A1 (en) Reverse-turn mimetics and methods relating thereto
DE69413085D1 (de) Immunsuppressive Aminomethylen-Peptide
WO2001016135A3 (en) Reverse-turn mimetics and methods relating thereto
CA2286733A1 (en) Reverse-turn mimetics and methods relating thereto
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
WO1995011309A3 (en) A novel nuclear mitotic phosphoprotein: mitosin
CA2195395A1 (en) Cyclic hexapeptide somatostatin analogues
ATE330968T1 (de) Cyclosporin-derivate und verfahren zu deren herstellung
BR0312889A (pt) Polipeptìdeo t20 peguilado
PT1107981E (pt) Sintese de analogos peptidicos ciclicos de anel modificado
CA2255865A1 (en) Synthesis of soluble beta-sheet forming peptides
CA2511888A1 (en) Deuterated cyclosporin analogs and their use as immunomodulating agents
ATE289612T1 (de) Diagnostische verwendungen von gegen acetylcholinesterase oder deren c-terminale peptide gerichteten antikörpern
CA2372639A1 (en) Deuterated cyclosporine analogs and their use as immunomodulating agents
DE69623635D1 (de) Mu-opioidligande: agonisten und antagonisten
EP0438600A4 (en) Enzymes which participate in c-terminal amidation, and production and use thereof
TR200002293T2 (tr) Farmasötik bileşimler.
CA2137037A1 (en) Fluorinated Diazabicycloalkane Derivatives
AU2002212623A1 (en) Compound for chelating a metal, radiopharmaceutical, manufacturing process therefor, and diagnostic kit

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ISOTECHNIKA,INC., EDMONTON, ALBERTA, CA

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 991660

Country of ref document: EP

Representative=s name: EISENFUEHR, SPEISER & PARTNER, 80335 MUENCHEN, DE